Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Vehicle-Controlled, Double-Blind, Multi-Center Study to Evaluate Safety and Efficacy of MBI 226 1.25% and 2.5% Acne Solutions Applied Topically for 12 Weeks to Subjects With Acne Vulgaris

NCT00211497 is registered in ClinicalTrials.gov with BioWest Therapeutics Inc as lead sponsor.

NCT NCT00211497
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00211497 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Vehicle-Controlled, Double-Blind, Multi-Center Study to Evaluate Safety and Efficacy of MBI 226 1.25% and 2.5% Acne Solutions Applied Topically for 12 Weeks to Subjects With Acne Vulgaris
Lead sponsor
BioWest Therapeutics Inc
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2003
Completion date
September 30, 2003
Enrollment
255
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acne, acne vulgaris, propionibacterium acnes